ATV Motocross @ Apex Genetics
Some shotgun flashing among the buildings at Apex Genetics -- http://www.twitch.tv/lepalose/c/2512633 utm_campaign=archive_export utm_source=lepalose utm_medium=youtube.

By: Lepalose

The rest is here:
ATV Motocross @ Apex Genetics - Video

Recommendation and review posted by Bethany Smith

Shaman Genetics

By: Nicolas Corales

More:
Shaman Genetics - Video

Recommendation and review posted by Bethany Smith

AMSTERDAM, THE NETHERLANDS--(Marketwired - Jul 9, 2013) - uniQure B.V., a leader in human gene therapy, today announced it has signed collaboration agreements with Chiesi Famaceutici SpA for the commercialization of Glybera, the first gene therapy to receive regulatory approval in Europe, as well as the co-development of a gene therapy for hemophilia B. In connection with this transaction, uniQure has received EUR 17 million (USD 21.8 million) in collaboration financing and EUR 14 million (USD 18 million) in equity financing from Chiesi, and has converted into equity the previously announced EUR 14.1 million (USD 18.1 million) investment led by Coller Capital (London, UK) with participation by existing investors.

uniQure's agreement with Chiesi, an international company headquartered in Parma, Italy, gives Chiesi exclusive rights to commercialize Glybera, the first gene therapy product approved in the European Union for the treatment of the orphan disease lipoprotein lipase deficiency (LPLD) for which there is currently no treatment, as well as for uniQure's pipeline product for hemophilia B, in Europe and selected other countries (Brazil, Mexico, Pakistan, Turkey, Russia, and the CIS countries, plus China for Glybera only). Commercial rights for the US, Japan, and parts of Latin America and Asia, and Australasia remain with uniQure. In exchange, uniQure stands to receive net royalties that range from 20 to 30 percent over time on sales of both products. Furthermore, Chiesi will fund half of the remaining development costs for uniQure's hemophilia B program, as well as take an equity stake in uniQure.

The investment by Chiesi will also result in the conversion into new uniQure shares of the EUR 14.1 million (USD 18.1 million) in convertible debt the Company recently raised from Coller Capital, a leading global private equity investor, and existing investors Forbion Capital Partners, Gilde Healthcare Partners, Lupus Alpha, Grupo Netco and others.

"The agreement with Chiesi is a key component of our strategy to rapidly develop and commercialize multiple gene therapy based treatments as well as being a validation of our technology platform," said Jrn Aldag, CEO of uniQure. "With its focus on innovative therapeutics, Chiesi is a strong partner for the commercialization of Glybera in Europe. The investment from Coller Capital, supplemented by our existing investors, allows us to continue apace with the development of what we believe is the richest and most advanced gene therapy pipeline in the industry. In the next 12-18 months, we anticipate clarifying the path toward an FDA filing for Glybera in the US, reporting results from a Phase I/II study in acute intermittent porphyria, and starting at least two Phase I/II studies for additional pipeline programs."

About uniQure uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. Our approach is validated by multiple partnerships and the regulatory approval of our lead product Glybera. http://www.uniqure.com.

About Chiesi Farmaceutici Founded in 1935 in Parma, Italy, Chiesi Farmaceutici currently has 25 affiliates worldwide and markets its therapeutics in over 60 countries. Chiesi's manufacturing plants in Parma, Blois (France) and Santana de Parnaiba (Brazil), and R&D centers in Parma, Paris, Rockville (USA) and Chippenham (UK) integrate their efforts to advance the Group's pre-clinical, clinical and registration programs. At the end of 2012, the Chiesi Group's total staff stood at over 3,800 people, more than 350 of whom are dedicated to R&D. The main areas of activity are in respiratory therapeutics and specialist medicine areas.

DisclaimerThis press release contains forward-looking statements based on uniQure's current expectations. These forward-looking statements include statements regarding the commercialization of Glybera, regulatory approval matters and the development of additional gene therapies. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties regarding further regulatory requirements, the success of further clinical trials, and competitive pressures. uniQure assumes no responsibility to update such forward-looking statements.

Press release (PDF): http://hugin.info/157414/R/1715194/569858.pdf

Read the original here:
uniQure Signs EU Commercialization Agreement With Chiesi Farmaceutici for First Approved Gene Therapy Treatment, and ...

Recommendation and review posted by Bethany Smith

20130707 Hong Kong Spinal Cord Injury Fund Charity Show - Violin Performance
Tanya #39;s first TV appearance, she is front row second from the right...

By: liqu1f1re

Here is the original post:
20130707 Hong Kong Spinal Cord Injury Fund Charity Show - Violin Performance - Video

Recommendation and review posted by sam

Purtier NZ Live Stem Cell Therapy presented by Dr Chen
For Live demo and discussion: Call John 90036287 / Daphne 91455217.

By: petty joy

Original post:
Purtier NZ Live Stem Cell Therapy presented by Dr Chen - Video

Recommendation and review posted by simmons

Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. Part 2
Improvement seen in just 3 months after Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy...

By: Neurogen Brain and Spine Institute

Read the original here:
Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. Part 2 - Video

Recommendation and review posted by simmons

by Buena Bernal Posted on 07/06/2013 9:06 PM |Updated 07/08/2013 2:15 PM

DOH ON STEM CELL. (Left) Health Secretary Enrique Ona and (right) FDA Director Kenneth Hartigan-Go talks to Rappler about stem cell therapy. Photos by Rappler/Naoki Mengua

MANILA, Philippines (UPDATED) Rappler talked to Department of Health (DOH) Secretary Enrique Ona and Food and Drug Administration (FDA) Director Kenneth Hartigan-Go to clarify the governments stance on stem cell therapy.

Stem cell therapy or regenerative medicine is a medical intervention that uses the bodys repair cells to substitute old cells. It is done for medical and aesthetic purposes that are still being investigated, according to the health secretary.

Asked why the treatment was allowed in the market despite no definitive curative and preventive benefits, FDA's Hartigan-Go said authorities never allowed the treatment to begin with.

Its just there. Now, the DOH under Secretary Ona's leadership took action," he said.

(READ: DOH: Stem cell therapy not yet proven to be curative)

On March 18, the DOH issued the rules and regulations for the accreditation of health facilities engaging in human stem cell and cell-based or cellular therapies in the Philippines.

The FDA has also released a circular on Monday, Jully 8, regarding the guidelines on registering stem cell-based products. The circular covers all products with a "claim, label, or poster" that says stem cells.

(READ: FDA Circular: Registration of Stem Cell-Based Products)

Originally posted here:
6 things you need to know about stem cell therapy

Recommendation and review posted by simmons

by Buena Bernal Posted on 07/06/2013 4:28 PM |Updated 07/08/2013 2:16 PM

STEM CELLS. Health Secretary Enrique Ona says stem cell therapy is a procedure still under clinical evaluation and study. Photo by Rappler/Naoki Mengua

MANILA, Philippines (UPDATED) Amid increasing interest in and the risks of stem cell treatment in the country, the health secretary said doctors are required to disclose to their potential patients that the procedure is still "investigative" its potential is still being explored, and there's no definite word that it can heal diseases.

This is in line with the ethical standards of medical practice that seek to empower patients with enough information prior to consenting to the treatment.

The patient must exactly know that he is part of an investigative process. And that is what we require as far as the Department of Health is concerned right now, Department of Health (DOH) Secretary Enrique Ona said in an interview with Rappler on Friday, July 5.

Stem cell therapy or regenerative medicine is the use of the bodys repair cells as a substitute to old cells that may cause debilitating diseases.

(READ: 6 things you need to know about stem cell therapy)

The treatment has gained controversy of late, after 3 unnamed high-profile politicians allegedly died due to botched procedures performed abroad. The deaths are currently being investigated by the Philippine Medical Association (PMA).

Not to stifle innovation

So why is the DOH encouraging the development of the science despite the treatment being under clinical evaluation and study?

Follow this link:
DOH: Stem cell therapy not yet proven to be curative

Recommendation and review posted by Bethany Smith

Scientists said Monday they had used a new-generation gene sequencing technique to select a viable embryo for in-vitro fertilisation (IVF) that yielded a healthy baby boy.

IVF, the process whereby a human egg is fertilised with sperm in the laboratory, is a hit-and-miss affair, with only about 30 percent of fertilised embryos resulting in pregnancy after implantation.

The reason for the high failure rate is not clear but genetic defects are the prime suspects, according to the authors of the paper presented Monday at a meeting in London of the European Society of Human Reproduction and Embryology (ESHRE).

The new method, known as next generation sequencing or NGS, uses updated technology to sequence an entire genome -- revealing inherited genetic disorders, chromosome abnormalities and mutations.

Study author Dagan Wells of the University of Oxford's NIHR Biomedical Research Centre said the new technology was "inherently cheaper" and yielded more genetic data than older methods.

It provides millions of fragments of DNA from a single cell which are then sequenced by a computer.

The method has started being used in genetic research and diagnostics, but not yet in embryo screening, according to Wells.

"Many of the embryos produced during infertility treatments have no chance of becoming a baby because they carry lethal genetic abnormalities," he said in a statement.

"Next generation sequencing improves our ability to detect these abnormalities and helps us identify the embryos with the best chances of producing a viable pregnancy."

Current methods of detecting embryonic gene deficiencies add over 2,000 (2,300 euros, $3,000) to a single IVF attempt, said Wells.

See the original post:
New gene sequencing yields healthy baby

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/8hsggg/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering.

Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally.

The evolution of biochips has opened new vistas in the biological systems. In addition, all other sciences are integrated which cumulatively contribute for a big future of biochip industry. The broad life science' division has been witnessing a rapid growth and technological improvements varying from sector to sector since the past 3-5 years. Accelerating growth rate exhibited by the biochips industry, even during the recession years, confirms the positive growth prospects going ahead. The field of drug discovery and development research gets more glamorous with the diagnostics and treatment at cellular level. DNA biochips and lab-on-chips have created revolution enabling the target validation. Genome scan is very soon going to become an ultimate weapon for diagnosis. In no time all the information related to genes will be sequenced, annotated and completed along with the list of diseases which are susceptible. Day to day the researchers are also making an effort to develop medication to control the various diseases, by using biochip technology. As the applications of biochips are wide both in the research and clinical use, a wide potential market is expected. The emergence of biochip technology can be attributed to a decade which has gradually developed into maturity. This industry is expected to bring rapid and significant changes in the life sciences and medicine. Microarray technologies have a great potential and is widely used in DNA and protein analysis.

The report reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations.

The report primarily focuses on:

- Emerging Market Trends

- Advancements in the Technological Space

- Market Demand Of The Segments (By-Region)

- Key Growth Areas and Market Size

Here is the original post:
Research and Markets: Analysis of Global Biochips Industry, 2012-2018

Recommendation and review posted by Bethany Smith

PISCATAWAY, N.J. , July 8, 2013 /CNW/ - GenScript, the world's largest provider of synthetic genes, has aided a leading biopharmaceutical company, Novavax, Inc. (NVAX), in developing an avian influenza A/H7N9 vaccine candidate, by synthesizing three constructs containing genes that encode for key vaccine proteins in just 6 business days. On May 10, 2013 , Novavax announced that its vaccine candidate was developed and entered into pre-clinical trials in only 28 days, less than 6 weeks after initial reports of H7N9 infections on April 1 .

The manufacture of the constructs used in Novavax's H7N9 vaccine candidate was powered by GenScript's Rush Gene Service , which synthesizes gene sequences in as few as 4 days. GenScript also offers free gene sequence optimization, which is advantageous for the production of vaccines and protein-based biologics. Normally, it takes researchers using traditional laboratory methods two weeks or more to assemble constructs like those used to produce an H7N9 vaccine. However, as demonstrated by the rapid development of Novavax' vaccine candidate, the combination of gene optimization, rush gene synthesis and custom cloning, facilitated by GenScript's one-stop service platform, can drastically reduce assembly time, accelerating research and development.

"Our mission is to save lives by helping scientists accelerate their research. In this case, our Rush Gene Services are the perfect example of our commitment to our mission," said GenScript CEO Frank Zhang , Ph.D. "The progress made by scientists at Novavax on its H7N9 vaccine candidate in such a short time is the reason why we are dedicated to providing high-quality services on a daily basis."

About GenScript

Founded in 2002, GenScript is a leading biology CRO specializing in customized biology research services including gene and peptide synthesis, protein expression, antibody generation and drug discovery/development. GenScript is headquartered in Piscataway, NJ , has subsidiaries in Europe , Japan , and China , and has over 1,300 employees, who are dedicated to providing biology research services to 86 countries worldwide. Learn more at http://www.genscript.com.

About Novavax

Novavax, Inc. (NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle technology, and efficient manufacturing approaches, Novavax produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and respond to rapidly spreading infections. Learn more at http://www.novavax.com.

SOURCE: GenScript USA Inc.

Excerpt from:
GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine

Recommendation and review posted by Bethany Smith

VEDBAEK, Denmark, July 8, 2013 (GLOBE NEWSWIRE) -- Exiqon A/S (EXQ.CO), a leading supplier of high-value products for gene expression analysis, today announced that Frost & Sullivan has recognized Exiqon as the recipient of the 2013 Company of the Year Award in Global microRNA Research Tools in light of the excellence that Exiqon has exhibited in the microRNA research space. This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.

Exiqon was one of the first companies to commercially serve the microRNA market and scientists around the world have published thousands of peer-reviewed scientific papers based on Exiqon's microRNA research products since the first product introductions in 2005.

Most recently, Exiqon has developed a database search tool, miRSearch, which allows customers to do simple and intuitive searches across a dozen relevant databases and easily navigate the overwhelming amount of microRNA information when designing experiments. The search tool is accessible at http://www.exiqon.com/mirsearch. This recent extension complements Exiqon's leading miRCURY LNA(tm) products for microRNA research that include validated microRNA products for sample extraction, gene expression and functional analysis, as well as advanced software for data analysis.

Exiqon has been cited as a preferred one-stop shop provider of complete workflow solutions pertaining to microRNA research. Provision of microRNA profiling and screening services along with products has not only simplified purchasing, but has also attracted new customers for Exiqon.

"Over the past eight years, the microRNA research space has evolved from an exotic research field to an emerging market which includes validated biomarkers and clinical applications," says Exiqon CEO Lars Kongsbak. "According to Frost & Sullivan analysis, Exiqon holds an average market share of 24 percent, thereby continuing to be instrumental in helping scientists across industry and academia understand and apply the biology of microRNAs".

Frost & Sullivan does not accept nominations or submissions for Frost & Sullivan Awards. The selection of this Award comes through in-depth interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.

Additional information from Exiqon

Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Additional information from Frost & Sullivan

Mireya Espinoza, Frost & Sullivan, Corporate Communications - North America, tel.: 210. 247.3870 (fax: 210.348.1003, e-mail: mireya.espinoza@frost.com)

Read the original post:
Exiqon Awarded Global microRNA Research Tools Company of the Year by Frost & Sullivan

Recommendation and review posted by Bethany Smith

By Dr. Gregory Jicha special to the Herald-Leader

A new gene variant has been linked to Alzheimer's disease, and this association is strongest among elderly blacks.

Though not the first gene to be linked to the condition, the identification of this gene variant is a breakthrough, as it reveals another way Alzheimer's may be triggered in the brain.

We in the medical profession have known for a long time that blacks over the age of 65 have a greater chance of developing Alzheimer's disease than do Caucasians the same age. Researchers have identified a gene (ABCA7) that helps explain this increased risk, according to a recent report in the Journal of the American Medical Association. The report, based on a large government-funded study, not only sheds new light on why blacks are at increased risk for the disease, but also offers a possible new focus of research in the battle against Alzheimer's.

ABCA7 is linked to production and metabolism of cholesterol and lipids. We have known for years that vascular problems stemming from high cholesterol and atherosclerosis seem to increase the risk of Alzheimer's disease. This discovery supports previous evidence that vascular health may be a particular contributor to the development of Alzheimer's among blacks. But we have also seen evidence that Alzheimer's is influenced by other genes, as well as by environmental factors and lifelong health habits. Taking this new evidence into consideration, it appears that there may be multiple mechanisms that control the onset and progression of this devastating disease.

From this evidence, it appears that there are variations of Alzheimer's disease, with different causes much like different types of cancer. If this is true, the treatment an individual receives may need to be tailored to the particular variant of the disease that they have. At this time, it is not recommended that individuals seek genetic testing for Alzheimer's because the relationship between the gene variants and the disease has not been firmly established. Many people have an associated gene variant, but do not go on to develop Alzheimer's.

Approximately five million people in the U.S. have Alzheimer's disease; this number is expected to more than triple by the year 2050, when the disease will cost $1.1 trillion annually. According to the Alzheimer's Association, it is the only disease among the top ten killers that has no effective treatment.

The discovery of ABCA7 provides us with a clear strategy for trying to reduce the risk for Alzheimer's in all of us, but most importantly for blacks. It shows the need to control your cholesterol and vascular risk factors. At the UK Alzheimer Disease Center/Sanders-Brown Center on Aging, we have recently been awarded two National Institute of Health grants focused on doing exactly this. These two studies are looking for volunteers with or without memory problems that want to lower their risk for Alzheimer's disease.

For more information on how you can get involved, please call Sarah at (859) 323-1331. Start lowering your risk today.

Dr. Jicha is the McCowan Endowed Chair in Alzheimer Research at the UK Sanders-Brown Center on Aging.

More:
Gene discovery offers new path for Alzheimer's research

Recommendation and review posted by Bethany Smith

Genetic engineering- Kinetic typography
There #39;s a lot of dispute over whether we should be changing the DNA to produce a certain feature or to even experiment with animals to only potentially lead ...

By: Oenaiwolf

Read the original here:
Genetic engineering- Kinetic typography - Video

Recommendation and review posted by Bethany Smith

In 2008, my 19-year-old daughter, Danielle, took the same type of DNA test for breast and ovarian cancer that actress Angelina Jolie took recently.

Jolie, 38, came out positive and opted for a preventive double mastectomy to dramatically reduce her risk of breast cancer, a too-often-lethal disease. She based her decision on a telltale pattern of mutations in the BRCA1 gene and a family history of breast cancer that claimed her aunt at age 61 and ovarian cancer that took her mothers life at 56.

The actress was told she had an 87 percent chance of developing breast cancer and a 50 percent chance of getting ovarian cancer, because of her particularly potent combination of family-illness history and genetics. This risk assessment, however, offered a level of genetic certainty for Jolie that is regrettably rare for most healthy people wanting to know if they have an elevated predisposition for a common disease like breast cancer. Only a few thousand breast-cancer patients in the United States share Jolies specific genetic mutations. The rest of the more than 230,000 cases annually diagnosed nationwide are caused by different genes or by other factors that cannot be as accurately predicted.

Danielle was tested for this unusual genetic signature in BRCA1 as part of a project I initiated over a decade ago as a journalist writing about genetics. At the time the $3 billion Human Genome Project was nearing completion, and hype about how the science of genomics would revolutionize medicine, allowing researchers to tailor drugs to specific diseases, made headlines. Pharmaceutical and biotech companies dreamed of big profits in personalized medicine, and ethicists worried about how people would react to their prospective risks to diseases and face the sort of difficult choices that Jolie did.

To better understand the complexities of DNA and wanting to humanize what could be eye-glazing science for non-geneticists, I had sections of my own DNA decoded first for a story published inWiredin 2002, and later for other stories and a book. My personal DNA odyssey culminated in 2011 when I got the entirety of my genome sequencedall six billion As, Ts, Cs and Gs. The idea was to see what this information could tell a healthy person about his or her future. My daughter, who seems to suffer from the same curiosity geneas yet unidentifiedas I do, insisted that she be tested alongside my parents and me as part of what became a family exploration to investigate three generations of one familys genetics.

As a father, I didnt like this idea at all. Testing myself and my parents, was one thing. They were in their late 70s and quite healthy, as I was in my 40s. This suggested that we didnt have anything dreadful in our DNA. But my daughter was a different case. Our family has a history of breast and ovarian cancers. My paternal grandmother survived breast cancer in her 50s and died of ovarian cancer at 86. I also knew from my previous testing that I am a carrier of gene markers other than BRCA1 that are associated with breast and ovarian cancers, as is my father, even though as males we had no risk of getting ovarian cancer, and a very low risk for breast cancer.

What if we found something amiss in Danielles genome, especially something we could do nothing about? Its bad enough to discover that you have a high chance of developing a disease without a cure, like Alzheimers, when youve had a long life behind you. Its quite another to receive information that casts a shadow over your future when youre young.

Another fear was that we would find out something that required us to make a difficult decision. Jolie faced the wrenching choice of either living with an 87 percent certainty of getting breast cancer in the future or removing her healthy breasts now. We were all anxious about the possibility of having to choose to pay a terrible price if we found out Danielle was at high risk for getting cancer or another serious disease.

I held my breath and ordered a scan of hundreds of thousands of Danielles genetic markers through a DNA testing company based in Iceland called deCODE Geneticswhich has since ceased offering this service. In addition, I ordered from Utah-based Myriad Genetics an earlier version of the BRCA1 test that was later taken by Jolie.

Thankfully, my daughters results on the Myriad test were negative, although this ruled out only one rare possibility that she might get these dreadful diseases. Later, Danielle did test positive for other DNA markers implicated in breast and ovarian cancersmarkers associated with several gene mutations that can contribute to a persons disease risks and chances for survival.

Link:
My family’s decade in genetic limbo

Recommendation and review posted by Bethany Smith

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review LiveRoom Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials The Lookout Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Lookout The Sideshow Around the World Katie's Take Power Players This Could Be Big Newsmakers Trending Now Just Explain It The Upbeat Local Popular Search Keyword News Search Featured Videos Photos Just Explain It Katie's Take Weather The Upbeat Newsmakers

Excerpt from:
MPM Capital Invests $3 Million, Takes Minority Stake in InformedDNA

Recommendation and review posted by Bethany Smith

The Chemical Imbalance, Genetics Biology of Bipolar Disorder: Myths of Psychiatry
http://www.bipolarorwakingup.com Most, if not all of what most people think about the relationship between genetics, chemical imbalance theory and bipolar di...

By: bipolarorwakingup

Read the original post:
The Chemical Imbalance, Genetics

Recommendation and review posted by Bethany Smith

AUSTRALIAN Texel breeders could have the opportunity to sell their genetics to New Zealand studs.

Eight New Zealand Texel studs will be attending this years Australian Sheep and Wool Show in a bid to learn more about Australian genetics.

Australian Texel Stud Breeders Association president Peter Russell said the Texel breed were the feature breed at this years show attracting the New Zealand studs to Australia.

I met some New Zealand breeders when I was judging at the Canterbury Show in Christchurch last year, Mr Russell said.

We spoke about the national showing and they were intrigued.

Now a group of them, about 15 people representing eight studs are coming across.

Mr Russell said Texel genetics were usually bought in from Europe but this would be a good opportunity for Australian breeders to show the attributes of their genetics.

The Australian Sheep and Wool Show will be held in Bendigo from July 19-21.

Originally posted here:
Texels studs to showcase genetics

Recommendation and review posted by Bethany Smith

LOS ANGELES, July 8, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has recently executed a provider contract with Blue Cross and Blue Shield of Illinois. Blue Cross and Blue Shield of Illinois has 7.4 million members, most of whom are located in the State of Illinois.

With the execution of this agreement, oncologists and pathologists affiliated with this health plan now have the ability to more easily offer Response Genetics' suite of molecular predictive testing for their patients battling lung, colon, gastric, and melanoma cancers. Response Genetics' tests provide treating physicians with actionable information that help enable the best therapy to be employed for each individual patient. The personalized medicine inherent in Response Genetics' testing services brings with it a value proposition that is expected to improve patient outcomes and as a result enhance efficiencies in health care delivery.

The contract with this Blue Cross Blue Shield Association affiliate complements Response Genetics' existing managed care network and gives the CLIA-licensed lab access to millions of additional Blue Cross Blue Shield-insured members located primarily in Illinois and the Midwestern United States. Blue Cross and Blue Shield of Illinois is the oldest and largest health plan based in Illinois.

About Blue Cross and Blue Shield of Illinois

Blue Cross and Blue Shield of Illinois ("BCBSIL"), a division of Health Care Service Corporation, a Mutual Legal Reserve Company, is the largest health insurance company in Illinois. Started in 1936, BCBSIL remains member owned rather than publicly traded and is committed to promoting the health and wellness of its members and its communities, fostering greater access to care, and working to lower the overall cost of care while improving the health care quality and patient outcomes.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX(R) products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

Read more:
Response Genetics, Inc. Announces Contract With Blue Cross and Blue Shield of Illinois

Recommendation and review posted by Bethany Smith

Dallas, Texas (PRWEB) July 07, 2013

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the world's leading healthcare companies:

Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Gene therapy partnering contract documents Top gene therapy deals by value

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals (http://www.reportsnreports.com/reports/262461-gene-therapy-partnering-terms-and-agreements.html). The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2007 including financial terms where available including over 300 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law?

The report also includes numerous tables and figures that illustrate the trends and activities in gene therapy partnering and dealmaking since 2007.

Visit link:
Gene Therapy Partnering Deals & Agreements By Healthcare Companies Analyzed in New Research Report at ReportsnReports ...

Recommendation and review posted by Bethany Smith

Treatment for Spinal Cord Injury with Stem Cells Therapy
Treatment for Spinal Cord Injury with Stem Cells Therapy, successfully results , after receiving the Stem Cells Treatment patient is regaining leg feeling an...

By: enjades

Read more here:
Treatment for Spinal Cord Injury with Stem Cells Therapy - Video

Recommendation and review posted by sam

Stem Cells For Spinal Cord Injury successfully results
Stem Cells For Spinal Cord Injury successfully results, Performed by NeuroSurgeon Dr. Luis Jorge Quintero, patient was treated with Stem Cells Therapy and ge...

By: enjades

See the rest here:
Stem Cells For Spinal Cord Injury successfully results - Video

Recommendation and review posted by sam

Michael - The Alliance for the Advancement of Adult Stem Cell Therapy and Research
The Alliance is here to assist people like Michael to receive adult stem cell treatment. Your donation WILL make a difference. If you #39;d like your donation to go to a specific person just mention...

By: TheStemCellAlliance

Follow this link:
Michael - The Alliance for the Advancement of Adult Stem Cell Therapy and Research - Video

Recommendation and review posted by simmons

Goodie Mobb- Cell Therapy (1995)
From their album, Soul Food.

By: MRSOWELLMUSIC

View post:
Goodie Mobb- Cell Therapy (1995) - Video

Recommendation and review posted by Bethany Smith

Manila, Philippines -- Philippine Medical Association (PMA) President Dr. Leo Olarte said yesterday Filipinos need not go abroad or seek foreign consultation if they want to undergo stem cell therapy to cure an ailment.

Olarte warned of the risks and complications involved in stem cell therapy when improperly administered, citing the case of a government official who complained of feeling weak after the procedure was performed on him by a group of foreign medical team inside a posh hotel in Mandaluyong City.

The PMA chief said there are local experts who are capable of performing safe and reliable stem cell treatments in the country using the patient's own stem cells.

The other day, a lawyer for Dangerous Drugs Board (DDB) Chairman Antonio Villar faced the media and revealed that her client is filing charges against the foreign medical team who performed the procedure on him.

Lawyer Claire Pagayanan said the lead doctor who performed the stem cell therapy was from Germany while the other two doctors and nurses who assisted him were from Thailand.

Villar reportedly paid 15,000 euros or approximately P1.2 million for the procedure.

"Doctors who perform this therapy should be licensed by the Philippine Food and Drugs Administration. Before foreign doctors could perform here, they should apply for a license from the Professional Regulation Commission," he said. Those who fail to do so will be in "clear illegal practice of medicine in violation of the Medical Act of 1959," Olarte added.

For his part, PMA spokesperson Dr. Mike Aragon lamented how colonial mentality has affected the decision-making process of some Filipinos. "Maybe they are not well-informed about stem cell therapy, or it is the colonial mentality. Many of us think that if it is foreign, it is something good," Aragon said.

In the country, the only Department of Health (DoH)-approved stem cells that can be used for treatment are the patient's own stem cells harvested from his or her blood, bone marrow and fat.

Read the original:
Stem cell therapy can be done in PH — PMA President

Recommendation and review posted by Bethany Smith